TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company

Transcenta, biologics, antibody

TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company

contact 中文

Press Release

15

Sep, 2020

Transcenta Successfully Scaled up the Continuous Perfusion Process and Completed GMP Manufacturing of a Novel Bispecific Antibody for Cancer Immunotherapy

Transcenta, a global biotherapeutics company, today announced success in scaling up the continuous perfusion process to 200L and completion of GMP production of a bispecific antibody for a Phase 1 clinical study.

07

Sep, 2020

Transcenta Holding Announces Appointment of Dr. Charlie Qi as Senior Vice President of Global Clinical Development

Transcenta Holding Limited (Transcenta), a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced the appointment of Dr. Charlie Qi as its Senior Vice President of Global Clinical Development.

31

Aug, 2020

Transcenta Announces First Patient Dosed in Phase I China Trial of Claudin18.2 Targeting Monoclonal Antibody TST001

Transcenta Holding Limited ("Transcenta"), a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announced today that the first subject has been dosed successfully on August 28th in China Phase I clinical trial of TST001, a humanized Claudin18.2 (CLDN18.2) monoclonal antibody developed by Transcenta's subsidiary Mabspace Biosciences (Suzhou) Co., Ltd. Transcenta conducts clinical trials of TST001 simultaneously in both China and the US, and the first subject has been dosed in the US on June 29th, 2020.

01

Jul, 2020

Transcenta Announces First Patient Dosed in Phase I Clinical Trial of Claudin18.2 Targeting Monoclonal Antibody TST001 in the US

Transcenta Holding Limited ("Transcenta"), a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announced today that the first subject has been dosed successfully in the US Phase I clinical trial of TST001, a humanized Claudin18.2 (CLDN18.2) monoclonal antibody developed by Transcenta's subsidiary Mabspace Biosciences (Suzhou) Co., Ltd.

27

May, 2020

Transcenta Presents First Data from Phase 1 Study of pH-Dependent PDL1 Antibody MSB2311 in Patients with Pre-treated Advanced Solid Tumors and Select Hematological Malignancies

Transcenta, a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announced today results reported for the first time from a Phase 1 - study (NCT04272944) of MSB2311, an investigational PDL1 targeting antibody with pH dependent and tumor recycling property developed by Transcenta's subsidiary Mabspace Biosciences (Suzhou) Co., Ltd, in the treatment of Chinese patients with pre-treated advanced solid tumors and select hematological malignancies.

21

May, 2020

Transcenta Announces to Present Preclinical Data of TST001 at 2020 AACR Virtual Annual Meeting II

Transcenta, a global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, development and manufacturing, today announced that it will present preclinical data of TST001, a humanized Claudin 18.2 (CLDN18.2) monoclonal antibody developed by its subsidiary Mabspace Biosciences, in a poster during the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II, being held from June 22-24.

1 2 3 4 5